Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer

Bo Zhong; Juxin Shen; Chunyi Zhang; Guozhong Zhou; Yuefang Yu; E Qin; Jixian Tang; Dongping Wu; Xiaochao Liang

doi:10.12659/MSM.924778

09 January 2021 : Clinical Research

Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer

Bo Zhong^1ACE, Juxin Shen^1AEG*, Chunyi Zhang^1BDE, Guozhong Zhou^2BE, Yuefang Yu^1DE, E Qin^1BE, Jixian Tang^1DE, Dongping Wu^3DE, Xiaochao Liang^1BE

DOI: 10.12659/MSM.924778

Med Sci Monit 2021; 27:e924778

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Plasma HSP90α levels at different times before and after chemotherapy.

Variable	Before chemotherapy	One cycle of chemotherapy	Two cycles of chemotherapy	Four cycles of chemotherapy	P value
HSP90	0.42 (0.29, 0.93)	0.41 (0.28, 0.76)	0.23 (0.14, 0.35)	0.17 (0.12, 0.24)	<0.001

Back to the Article

Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer

Your Privacy